The estimated Net Worth of Jeffrey Eisele is at least $3.63 millió dollars as of 29 January 2024. Jeffrey Eisele owns over 1,250 units of Apellis Pharmaceuticals Inc stock worth over $2,194,499 and over the last 4 years Jeffrey sold APLS stock worth over $1,435,505.
Jeffrey has made over 9 trades of the Apellis Pharmaceuticals Inc stock since 2023, according to the Form 4 filled with the SEC. Most recently Jeffrey sold 1,250 units of APLS stock worth $81,525 on 29 January 2024.
The largest trade Jeffrey's ever made was selling 7,378 units of Apellis Pharmaceuticals Inc stock on 23 January 2024 worth over $469,905. On average, Jeffrey trades about 1,160 units every 19 days since 2020. As of 29 January 2024 Jeffrey still owns at least 57,208 units of Apellis Pharmaceuticals Inc stock.
You can see the complete history of Jeffrey Eisele stock trades at the bottom of the page.
Jeffrey's mailing address filed with the SEC is C/O APELLIS PHARMACEUTICALS, INC., 100 FIFTH AVENUE, 3RD FLOOR, WALTHAM, MA, 02451.
Over the last 6 years, insiders at Apellis Pharmaceuticals Inc have traded over $44,114,337 worth of Apellis Pharmaceuticals Inc stock and bought 1,248,415 units worth $38,006,599 . The most active insiders traders include Venture Investments Ltd Mor..., Cedric Francois és Pascal Deschatelets. On average, Apellis Pharmaceuticals Inc executives and independent directors trade stock every 6 days with the average trade being worth of $665,393. The most recent stock trade was executed by James George Chopas on 3 September 2024, trading 550 units of APLS stock currently worth $21,720.
apellis pharmaceuticals is an early stage biotechnology company applying immunotherapy to auto-immune diseases, with an initial emphasis on diseases of the lungs such as asthma and chronic obstructive pulmonary disease (copd), diseases of the retina such as age-related macular degeneration (amd), and rare hematological diseases such as paroxysmal nocturnal hemoglobinuria (pnh). apellis believes that targeting a key element in the immune system called the complement system can have profound disease modifying benefits. we call this approach complement immunotherapy.
Apellis Pharmaceuticals Inc executives and other stock owners filed with the SEC include: